Impact of High-Density Lipoproteins on Sepsis.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing preclinical mechanisms, observational epidemiology, and Mendelian randomization studies without systematic methodology.
PubMed 36361756 · doi:10.3390/ijms232112965
What was done
This narrative review synthesized evidence across biochemistry, pathophysiology, observational epidemiology, Mendelian randomization studies, and preclinical animal interventions examining the role of high-density lipoproteins (HDL) and HDL-associated enzymes in sepsis.
What was found
The abstract provides no numerical data, effect estimates, or confidence intervals. It qualitatively reports that HDL sequesters and neutralizes pathogen-associated lipids via the reverse lipopolysaccharide transport pathway and exhibits direct anti-inflammatory actions. It also notes that observational and Mendelian randomization studies link low HDL cholesterol to increased risk of infectious hospitalizations and adverse sepsis prognosis, and identifies apolipoprotein A-I, recombinant PLTP, and CETP inhibition as potential therapeutic targets.
Why it matters
The review outlines how HDL acts as part of the innate immune response to clear pathogen lipids, pointing to possible HDL-targeted therapeutic strategies for sepsis.
Limits
The paper is a non-systematic narrative review providing no quantitative synthesis or search methodology. Human randomized interventional trials testing HDL-raising therapies are absent from the abstract.
Cited by
- supports All classes of plasma lipoproteins are capable of binding bacterial lipopolysaccharide (endotoxin).